Molecule Information
General Information of the Molecule (ID: Mol01224)
Name |
WT1 antisense RNA (WT1-AS)
,Homo sapiens
|
||||
---|---|---|---|---|---|
Synonyms |
WT1-AS
Click to Show/Hide
|
||||
Molecule Type |
LncRNA
|
||||
Gene Name |
H_RG012D21.9, LINC00096, TP53AP1
|
||||
Gene ID | |||||
Location |
chr11:32435518-32500632[+]
|
||||
Ensembl ID | |||||
HGNC ID | |||||
Click to Show/Hide the Complete Species Lineage | |||||
Type(s) of Resistant Mechanism of This Molecule
EADR: Epigenetic Alteration of DNA, RNA or Protein
Drug Resistance Data Categorized by Drug
Approved Drug(s)
1 drug(s) in total
Doxorubicin
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Epigenetic Alteration of DNA, RNA or Protein (EADR) | ||||
Disease Class: Hepatocellular carcinoma | [1] | |||
Sensitive Disease | Hepatocellular carcinoma [ICD-11: 2C12.2] | |||
Sensitive Drug | Doxorubicin | |||
Molecule Alteration | Expression | Up-regulation |
||
Experimental Note | Revealed Based on the Cell Line Data | |||
Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
Cell proliferation | Inhibition | hsa05200 | ||
JAKT2/STAT3/MAPK signaling pathway | Inhibition | hsa04659 | ||
In Vitro Model | HepG2 cells | Liver | Homo sapiens (Human) | CVCL_0027 |
L02 cells | Liver | Homo sapiens (Human) | CVCL_6926 | |
Experiment for Molecule Alteration |
qPCR | |||
Experiment for Drug Resistance |
EDU assay; Flow cytometry assay | |||
Mechanism Description | WT1-AS promotes cell apoptosis in hepatocellular carcinoma through down-regulating of WT1.WT1-AS expression correlated negatively with WT1 expression in HCC tumor tissue. kaplan-Meier curve analysis revealed that WT1-AS expression is a reliable indicator of HCC prognosis. The downregulation of WT1 expression by WT1-AS promoted cell apoptosis by suppressing the JAk/STAT3 signaling pathway. Bioinformatics analysis showed that WT1-AS downregulates WT1 by binding to the TATA region of the WT1 promotor. WT1-AS was also able to reverse WT1-mediated resistance to Dox based chemotherapy in HCC cells. |
Disease- and Tissue-specific Abundances of This Molecule
ICD Disease Classification 02
Liver cancer [ICD-11: 2C12]
Differential expression of molecule in resistant diseases | ||
The Studied Tissue | Bile duct | |
The Specified Disease | Cholangiocarcinoma | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 2.25E-01; Fold-change: -5.86E-01 | |
Molecule expression in the diseased tissue of patients
Molecule expression in the normal tissue of healthy individuals
|
||
Disease-specific Molecule Abundances | Click to View the Clearer Original Diagram | |
The Studied Tissue | Liver | |
The Specified Disease | Liver hepatocellular carcinoma | |
The Expression Level of Disease Section Compare with the Healthy Individual Tissue | p-value: 2.35E-02; Fold-change: -3.18E-01 | |
Molecule expression in the diseased tissue of patients
Molecule expression in the normal tissue of healthy individuals
|
||
Disease-specific Molecule Abundances | Click to View the Clearer Original Diagram | |
Tissue-specific Molecule Abundances in Healthy Individuals
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.